| Name | Title | Contact Details |
|---|
Comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes
Vium is the first company to create a living informatics platform for preclinical in vivo drug research.
Reaction Biology provides scientists worldwide with a trusted research partner supporting all phases of preclinical drug discovery from target validation through hit identification, hit to lead and lead optimization. Our portfolio covers most of your needs in drug discovery – over 1,000 biochemical targets, hundreds of cell-based assays, an extensive array of in vivo oncology models, along with custom assay development and protein production. Our team of Ph.D. scientists will provide you with collaborative support, quality data, and excellent communication, for a superior research result.
Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Massachusetts (USA).
A disruptive new biopharmaceutical CDMO, we are pushing the boundaries of biomanufacturing and solving an outdated industry bottleneck with a unique partnering model. By bringing together biologics drug innovators, discovery CROs, and CDMOs, we are accelerating the translation of therapeutic innovation to clinical impact.